A5066028226- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Cell Adhesion Molecules Research
- Retinal and Optic Conditions
- Atherosclerosis and Cardiovascular Diseases
- Dermatological and Skeletal Disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Ocular Diseases and Behçet’s Syndrome
- Lipid metabolism and disorders
- Autoimmune Bullous Skin Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Neuropeptides and Animal Physiology
- Asthma and respiratory diseases
- Healthcare Systems and Reforms
- Protein Structure and Dynamics
- Genomics, phytochemicals, and oxidative stress
- Clusterin in disease pathology
- Glutathione Transferases and Polymorphisms
- Healthcare Systems and Practices
- Myofascial pain diagnosis and treatment
- Cerebral Venous Sinus Thrombosis
- Diabetes, Cardiovascular Risks, and Lipoproteins
Novartis (France)
2010-2023
Novartis (Netherlands)
2023
Novartis (Switzerland)
2013
Centre Hospitalier Universitaire d'Angers
2007-2010
Inserm
2003-2009
Université de Lorraine
2009
Laboratoire de Microbiologie et Génétique Moléculaires
2004
Centre de Médecine Préventive
2003
To present interim descriptive insights from the OCTOPUS and SWIFT studies on incidence, clinical features, management, outcomes of intraocular inflammation (IOI), vasculitis, occlusive vasculitis with brolucizumab treatment (Beovu, Novartis) in patients neovascular age-related macular degeneration (nAMD) who were anti-VEGF naive or pretreated anti-VEGFs (ranibizumab aflibercept).OCTOPUS (NCT04239027) (NCT04264819) are prospective phase IIIb single-arm, open-label, multicenter assessing...
PurposeThis study aimed to estimate the incidence and prevalence of neovascular age-related macular degeneration (nAMD) in French population between 2008 2018.DesignThis was a retrospective, longitudinal using health care consumption data from Système National des Données de Santé (SNDS; Health Information Database), which covers approximately 99% population.ParticipantsWe identified individuals treated for nAMD 50 years age older. Identification criteria were diagnosis or reimbursement...
To report the real-world effectiveness and safety of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME).This is a French, 36-month, multicenter, observational cohort study. Between December 2013 April 2015, ophthalmologists enrolled aged ≥18 years DME-related for whom was initiated. Here, we present 12-month results from this cohort. The primary endpoint mean change best-corrected acuity (BCVA); sample size calculations were based on RESTORE trial data...
To evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) a real-world setting. A descriptive, observational, multicenter study retrospective prospective cohort was conducted France that included who had received at least one injection during period October 2011 2014, for CNV PXE. Eligible were identified by review medical records or routine consultations. The main objectives...
Intercellular adhesion molecule-1 (ICAM-1) and E-, P-, L-selectin are cellular molecules involved in the recruitment of leukocytes on activated vessel wall during inflammation (1) play an important role early stages atherosclerosis its complications (2). Thus, measurement soluble serum may have diagnostic relevance many inflammatory diseases (3). A profile molecule concentrations allow better therapeutic decisions autoimmune disorders, infection, cancer, cardiovascular pathologies also aid...
Abstract Objective To describe the management of diabetic macular oedema (DME) patients from entire French population between 2012 and 2018. Methods In this retrospective longitudinal study, we identified adults treated for DME using exhaustive National Health Information database (SNDS), an algorithm based on diagnosis procedure codes, reimbursed treatments. Results Between 2018, 53 584 patients, who were followed up to 7 years treatment initiation. Optical coherence tomography (OCT) became...
Aim: LANDSCAPE aimed to estimate the annual incidence and prevalence of treated diabetic macular edema (DME) proliferative retinopathy (PDR) between 2008 2018. Methods: This French nationwide observational study used data from National Health Insurance Databases covering 99% population. Data about healthcare consumption were identify adults with anti-VEGFs or dexamethasone implants (for DME) pan-retinal photocoagulation PDR). All patients newly 2018 included. Incidence DME PDR estimated for...
Introduction. The most recent guidelines on asthma management advocate a treatment strategy based control of the disease rather than severity, switch reported evidence. Aims. This observational, questionnaire-based study set out to investigate how is assessed by physician as well patient and his/her live-in partner compare these assessments with an assessment made according guidelines. Methods. In 169 patients severe, persistent at least high-dose inhaled corticosteroid plus long-acting...
To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) adults with decreased VA due to diabetic macular edema (DME).Real-world prospective observational 24-month study. Ranibizumab-naïve patients (n=116) were enrolled, treated and followed up according investigators' usual procedures. Outcomes included change from baseline month 24 best-corrected (BCVA; primary outcome), central retinal thickness (CRT), treatment exposure...
The aim of this study was to describe the management neovascular age-related macular degeneration (nAMD) in French patients between 2008 and 2018. This a retrospective longitudinal cohort using exhaustive nationwide health records from National Health Information database. Enrollment criteria were adults aged ≥ 50 years, nAMD diagnosis, or reimbursement for treatments (anti-vascular epithelial growth factor [VEGF] injection dynamic phototherapy with verteporfin). Exclusion high myopia,...